Povorcitinib Improves Facial Pigmentation in Two Phase 3 Vitiligo Trials

Vitiligo causes patches of skin to lose pigment when the immune system attacks pigment-producing cells. For adults with widespread disease, an effective oral treatment could offer another option beyond treatments applied directly to the skin. Two major trials now suggest that povorcitinib can substantially improve facial pigmentation in some patients.

Researchers conducted two randomized, double-blind, placebo-controlled phase 3 trials involving 916 adults with moderate-to-severe nonsegmental vitiligo. Participants received either povorcitinib, a selective JAK1 inhibitor taken as a 30 mg daily pill, or placebo. The main outcome was whether patients achieved at least a 75% improvement in a standardized facial vitiligo score after 52 weeks, rather than complete clearance of all affected skin.

In both studies, 18.9% of povorcitinib recipients reached that target. Placebo response rates were 6.8% and 3.1%, respectively. These differences were statistically significant and corresponded to approximately 12 and 16 additional responders per 100 treated adults. However, about four in five patients taking povorcitinib did not reach this demanding facial improvement threshold within one year.

Overall adverse events occurred in roughly 67% to 69% of treated patients versus 63% to 64% receiving placebo. Acne was more common with povorcitinib, affecting about 11% versus 2% to 3%. Common events also included colds and upper respiratory infections. Serious events were generally isolated, while events associated with the JAK inhibitor class were absent or rare.

These findings support further consideration of povorcitinib as a systemic option, not proof of a cure or improved longevity. The abstract does not establish regulatory approval, comparative effectiveness against existing treatments, or lasting benefit after stopping therapy. This summary relies on the abstract only; detailed methods and safety tables were unavailable. Several authors disclosed industry relationships, including employees and shareholders of Incyte. Larger, longer follow-up remains important for assessing uncommon harms and durability of pigment recovery.